TherapeuticsMD stock slips 3.32% and underperforms competitors

6 articles · Updated · MarketWatch · Apr 30

Shares closed at $2.04 on Thursday as the Nasdaq rose 0.89% to 24,892.31 and the Dow gained 1.62% to 49,652.14.
The decline ended a two-day winning streak, while AbbVie shares outperformed with a 3.64% rise to $211.32.
TherapeuticsMD finished 30.85% below its 52-week high of $2.95 reached on 27 January, and trading volume of 19,198 was below its 50-day average.

With its future on the line, can TherapeuticsMD survive its high-stakes legal battle against a much larger rival?

As AbbVie thrives post-patent cliff, is TherapeuticsMD's royalty model a sustainable strategy or a slow decline toward a buyout?

Is AbbVie's huge investment in US manufacturing a genius move for future growth or a risky bet on its pipeline?